Combination endocrine therapy and CDK4/6 inhibition have become the standard of care for people with hormone receptor–positive/HER2-negative metastatic breast cancer. Nancy Chan, MD, clinical research director for breast cancer at NYU Langone Health’s Perlmutter Cancer Center, talks with MedPage Today about advances in the use of targeted therapies that are poised to replace chemotherapy, which is typically considered after the disease progresses on combination hormone therapy.

“The most important factor in how we choose the next line of treatment is knowing the patient sitting in front of us,” says Dr. Chan, also a member of the faculty of the Department of Medicine at NYU Grossman School of Medicine. “Clinical judgment is still a very important part of how we treat breast cancer. We have to use it to determine how to sequence and use all the new drugs available.”

Read more from MedPage Today.